ArticleAdvances in therapy2026
Real-World Safety and Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma: Final Analysis of a Post-Marketing Surveillance in Japan.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionFluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) is approved for the treatment of asthma in Japan. Currently, data on the safety, particularly on cardiovascular (CV) risk, and effectiveness of FF/UMEC/VI in Japanese real-world clinical practice are limited.
methodsThis prospective, multicenter, post-marketing surveillance was undertaken to assess the safety and effectiveness of once-daily single-inhaler triple therapy FF/UMEC/VI (100/62.5/25 or 200/62.5/25 mcg) newly initiated in patients with asthma in Japan between July 2021 and November 2023. The observation period was 1 year after the first FF/UMEC/VI prescription or until termination or withdrawal from treatment. Safety was assessed by incidence of adverse drug reactions (ADRs) including CV events as safety specification to be checked due to risk associated with use of UMEC. Overall assessment of effectiveness (based on lung function, asthma symptoms, and proportion of patients with exacerbation events) and asthma management status was assessed by the investigator.
resultsOverall, 8.4% (24/286) of patients reported an ADR. The most common ADRs were cough and dysphonia (each 7/286). Urinary retention was reported as a serious ADR in 1 patient, and CV event palpitations were reported in 2 patients. FF/UMEC/VI treatment was deemed effective in 92.5% (260/281) of patients in the effectiveness analysis. Lung function and asthma control test results improved following initiation of FF/UMEC/VI. In the 1 year after initiation, 6.2% (11/178) of patients experienced exacerbation events, while 25.8% (46/178) of patients experienced exacerbation events prior to initiation.
conclusionFF/UMEC/VI was well tolerated and effective in the treatment of patients with asthma in Japan. ADRs were reported in 8.4% of patients and the incidence of CV events was low. No new safety concerns were identified.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.